Fulcrum Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Fulcrum Therapeutics, Inc. (FULC), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are FULC insiders buying or selling?
In the last 12 months, Fulcrum Therapeutics, Inc. insiders reported 2 open-market purchases ($1.5M) and 7 sales ($59.2M) — net selling of $57.7M. Since July 2019, Trabud has recorded 68 Form 4 filings for FULC: 18 buys ($51.6M) and 50 sells ($66.7M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $891.1K by Kevin Tang (10% Owner) on Jul 15, 2026. SEC ↗
- The most recent open-market purchase was reported on Jul 21, 2026 (2 months ago).
Key Statistics (July 2019 – Jul 21, 2026)
Total Form 4 filings
68
SEC EDGAR
Insider filers
20
Insider buys (18)
$51.6M
Insider sells (50)
$66.7M
Insider sentiment
Net sellingNet insider flow of $15.1M in net selling since July 2019, and $57.7M in net selling over the last 12 months.
Recent FULC insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 21, 2026 | Kevin Tang | 10% Owner | Purchase | 167.6K | $3.55 | $594.7K | SEC ↗ |
| Jul 15, 2026 | Kevin Tang | 10% Owner | Purchase | 249.9K | $3.56 | $891.1K | SEC ↗ |
| Jun 30, 2026 | Alan Ezekowitz | Director | Sale | 18.0K | $3.65 | $65.6K | SEC ↗ |
| Feb 4, 2026 | Robert J Gould | Director | Sale | 15.0K | $10.87 | $163.1K | SEC ↗ |
| Feb 4, 2026 | Robert J Gould | Director | Sale | 15.0K | $10.72 | $160.9K | SEC ↗ |
| Jan 6, 2026 | Robert J Gould | Director | Sale | 15.0K | $11.87 | $178.1K | SEC ↗ |
| Dec 17, 2025 | Curtis Gale Oltmans | Chief Legal Officer | Sale | 3.5K | $12.92 | $44.6K | SEC ↗ |
| Dec 10, 2025 | Peter Kolchinsky | 10% Owner | Sale | 4.2M | $13.98 | $58.4M | SEC ↗ |
| Nov 21, 2025 | Robert J Gould | Director | Sale | 15.0K | $11.03 | $165.5K | SEC ↗ |
| May 9, 2025 | Greg Tourangeau | Principal Accounting Officer | Sale | 498 | $5.06 | $2.5K | SEC ↗ |
| May 9, 2024 | Greg Tourangeau | Principal Accounting Officer | Sale | 236 | $7.76 | $1.8K | SEC ↗ |
| Mar 8, 2024 | Greg Tourangeau | Vice President, Finance | Sale | 4.9K | $11.72 | $57.2K | SEC ↗ |
| Mar 5, 2024 | Alex Sapir | President & Chief Executive Officer | Purchase | 43.4K | $11.35 | $492.0K | SEC ↗ |
| May 11, 2023 | Greg Tourangeau | Principal Accounting Officer | Sale | 210 | $3.31 | $695.1 | SEC ↗ |
| Jan 24, 2023 | Peter Kolchinsky | 10% Owner | Purchase | 1.9M | $13.00 | $25.0M | SEC ↗ |
| Jan 13, 2023 | Robert J Gould | Interim President & CEO | Sale | 6.8K | $15.00 | $101.5K | SEC ↗ |
| Jan 6, 2023 | Peter Kolchinsky | 10% Owner | Purchase | 180.7K | $7.28 | $1.3M | SEC ↗ |
| Dec 29, 2022 | Peter Kolchinsky | 10% Owner | Purchase | 4.1K | $5.99 | $24.5K | SEC ↗ |
| Dec 21, 2022 | Peter Kolchinsky | 10% Owner | Purchase | 98.8K | $5.90 | $582.8K | SEC ↗ |
| Dec 16, 2022 | Peter Kolchinsky | 10% Owner | Purchase | 2.4M | $5.44 | $13.1M | SEC ↗ |
| Jun 8, 2022 | Robert J Gould | Director | Sale | 71.4K | $8.09 | $577.9K | SEC ↗ |
| Jun 6, 2022 | Robert J Gould | Director | Sale | 66.6K | $8.00 | $532.8K | SEC ↗ |
| Apr 11, 2022 | Robert J Gould | Director | Sale | 5.6K | $24.02 | $135.2K | SEC ↗ |
| Apr 5, 2022 | Robert J Gould | Director | Sale | 94.3K | $24.16 | $2.3M | SEC ↗ |
| Aug 12, 2021 | Christopher Moxham | Chief Scientific Officer | Sale | 51.8K | $17.60 | $911.4K | SEC ↗ |
Showing the 25 most recent of 68 Form 4 filings for Fulcrum Therapeutics, Inc..
Most active FULC insiders
- Robert J Gould21 filings
- Diego Cadavid9 filings
- Owen B. Wallace6 filings
- Peter G. Thomson6 filings
- Peter Kolchinsky6 filings
Ask anything about FULC insider activity
Use Trabud's AI agent to query Fulcrum Therapeutics, Inc.'s Form 4 history in plain English — "Show me FULC CEO purchases this year" or compare it against any other ticker.
Open the AI agentFULC insider trading FAQ
Are Fulcrum Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Fulcrum Therapeutics, Inc. insiders reported 2 open-market purchases ($1.5M) and 7 sales ($59.2M) — net selling of $57.7M. Since July 2019, Trabud has recorded 68 Form 4 filings for FULC: 18 buys ($51.6M) and 50 sells ($66.7M). Over the full record that is net selling of $15.1M.
How many insiders trade FULC stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Fulcrum Therapeutics, Inc.. The most recent filing was accepted on Jul 21, 2026.
Where does Trabud get FULC insider trading data?
All FULC insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.